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cense.Abstract Introduction: The pathogenesis of systemic sclerosis (SSc) involves interplay between
obliterative vasculopathy in multiple vascular beds, inﬂammation, autoimmunity and progressive
ﬁbrosis. Vascular injury and activation are the earliest and possibly primary events in the pathogen-
esis of SSc.
Aim of the work: To determine levels of serum soluble fractalkine (sFKN) and its receptor
CX3CR1 in peripheral blood mononuclear cells (PBMCs) in systemic sclerosis (SSc) patients and
healthy controls. In addition, to assess any possible association between sFKN and clinical features
of SSc.
Patients and methods: Serum levels of soluble fractalkine (sFKN, CX3CL1) assessed by enzyme
linked immunosorbent assay (ELISA) and expression of its receptor (CX3CR1) on peripheral blood
mononuclear cells by ﬂow cytometric analysis, were measured in 18 systemic sclerosis (SSc) patientsail.com (M. El-Sergany),
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94 M. El-Sergany et al.and 15 age and sex matched healthy controls. The degree of skin involvement was estimated by
modiﬁed Rodnan skin thickness score (mRSS), pulmonary involvement was assessed in all patients
by high resolution computerized tomography (HRCT) and pulmonary function tests (PFTs).
Results: Serum sFKN levels and expression of its receptor CX3CR1 were signiﬁcantly elevated in
SSc patients than in healthy controls (P< 0.0.05). SSc patients with pulmonary ﬁbrosis had sFKN
levels three times higher than those without PF. Serum sFKN correlated inversely with forced vital
capacity of lungs (FVC%) but correlated positively with severity of pulmonary ﬁbrosis, extent of
skin ﬁbrosis (mRSS), pitting scars, skin ulcers, anti topo-isomerase1antibody and CRP.
Conclusion: Serum sFKN may play an important role in the pathogenesis of SSc, including tissue
inﬂammation and vascular injury, hence, its measurement may be a useful serologic marker for the
diagnosis and follow up of pulmonary and skin complications. So strategies to target CX3CL1–
CX3CR1 interaction could provide a new therapeutic approach in SSc, potentially by blocking
endothelial cell injury, leucocyte inﬁltration, and vascular injury.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Systemic sclerosis (SSc) is an autoimmune disease character-
ized early by vasculopathy and subsequently by varying the
degree of ﬁbrosis in skin, lungs and other tissues. The presence
of ﬁbrosis is the hallmark of this disease [1].
The pathogenesis of SSc involves an interplay between
obliterative vasculopathy in multiple vascular beds, inﬂamma-
tion, autoimmunity and progressive ﬁbrosis [2,3]. Vascular in-
jury and activation are the earliest and possibly primary events
in the pathogenesis of SSc [4].
Endothelial cell (EC) dysfunction is a common feature in
several immune-mediated inﬂammatory diseases, including
vasculitis 4. Activated ECs amplify and perpetuate inﬂamma-
tory processes by expressing and secreting a variety of cyto-
kines, chemokines, cell-mediated molecules, and other
inﬂammatory molecules. Moreover, interaction between ECs
and invading mononuclear cells is essential for the progression
of vasculitis [5].
Pulmonary complications are one of the most challenging
complications of systemic sclerosis [6]. Pulmonary ﬁbrosis
(PF) develops in more than 50% of SSc patients and is the ma-
jor cause of death [7].
To assess the activity of PF, previous studies have identiﬁed
several important signs, including patchy areas with a ground-
glass or reticular appearance on high-resolution computed
tomography (HRCT) [7]. Recently HRCT plays a key role in
determining the prognosis of patients with SSc [8]. However,
easier, less-invasive, serologic markers would be helpful for
closely monitoring the activity of PF in SSc patients.
For a considerable time, skin involvement in SSc was regu-
lated as a surrogate marker for internal organ involvement [9].
However, recently it was shown that improvement of skin scle-
rosis, spontaneously or as a result of treatment, does not nec-
essarily reﬂect improvement of organ involvement [10]. Thus
the failure of skin ﬁbrosis to serve as a surrogate marker for
severe manifestation in SSc stressed the importance of ﬁnding
better and more predictive markers for life threatening disease
complications.
The chemokine fractalkine (FKN; CX3CL1) is a unique
member of CX3C chemokine subfamily. In contrast to other
chemokines, it exists in two forms, each mediating distinct bio-
logical actions [11]. The membrane-anchored protein, which isprimarily expressed on the inﬂamed endothelium, serves as an
adhesion protein promoting the retention of monocytes and T
cells in inﬂamed tissue. The soluble form resembles more of a
conventional chemokine and strongly induces chemotaxis.
Both chemotaxis and adhesion are mediated by the G pro-
tein-coupled receptor CX3CR1 [12,13].
sFKN localized on the endothelial cells not only promotes
leucocyte activation but, unlike other chemokines, can also
mediate each individual step of the leucocyte adhesion cascade,
including capture, rolling, and ﬁrm adhesion [14,15]. Accumu-
lating evidence suggests that sKN–CX3CR1 interaction might
contribute to the development of vascular injury and inﬂam-
matory diseases, by recruiting activated leucocytes [15–17].
The levels of CX3CL1 expression by ECs are low in healthy
individuals in the absence of an inﬂammatory insult, but at
sites of inﬂammation, the levels of both the membrane-bond
and secreted forms are greatly up regulated by inﬂammatory
cytokines [11]. Thus, CX3CL1 appears to possess immunoreg-
ulatory properties that affect inﬂammatory and immune cell–
EC interactions and inﬂammatory responses at inﬂamed sites.
Indeed, investigations by several groups have implicated
CX3CL1 in a variety of inﬂammatory disorders, including glo-
merulonephritis, RA, systemic sclerosis and SLE [18,12].
2. Aim of the work
The aim of the present study was to determine the serum levels
of sFKN (CX3CL1) and its receptor (CX3CR1) on peripheral
blood mononuclear cells, In addition, to assess any possible
association between sFKN and clinical features of the disease.
3. Patients and methods
A total of 18 non smoking female SSc patients who fulﬁlled the
criteria proposed by the American College of Rheumatology
for SSc [19] were enrolled in this study. The mean age of the
patients was 37.3 ± 4.2 years and the mean disease duration
was 7.8 ± 5.4 years. Disease duration was calculated from
the time of the ﬁrst clinical event: Raynaud’s phenomenon,
the ﬁrst presence of skin involvement or the ﬁrst presence of
organ involvement .Informed consent was obtained from all
patients.
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controls for fractalkine, its receptor CX3CR1 and C-reactive
protein (CRP) measurement.
3.1. Exclusion criteria
Cigarette smoking or recent history of infection or other sys-
temic inﬂammatory diseases.
3.1.1. Clinical assessment
Complete medical histories were obtained, physical examina-
tions, laboratory tests (ESR, CRP, kidney function tests, com-
plete urine analysis) and immunological tests (anticentromere
antibody, anti-topoisomerase I antibody and ANA) were con-
ducted for all patients at their ﬁrst visit with evaluations espe-
cially for pulmonary function during follow up visits. Skin
thickness was scored according to the modiﬁed Rodnan skin
thickness score (mRSS) by summing the skin thickness mea-
surements as determined by palpation on a 0–3 scale in 17
body areas (range 0–51) [20].
Organ system involvement was deﬁned as described previ-
ously [21,22] lung = bibasilar ﬁbrosis on chest radiography
and high resolution computed tomography; isolated pulmon-
ary hypertension, color Doppler echocardiography for the def-
inition of PAH. A pulmonary artery systolic pressure (PASP)
>35 mm Hg was used to deﬁne PAH; esophagus = hypomo-
bility shown by barium radiography; joint = inﬂammatory
polyarthralgia or arthritis; heart = pericarditis, congestive
heart failure, or arrhythmias requiring treatment; kid-
ney = malignant hypertension and rapidly progressive renal
failure without any other explanation; and muscle = proximal
muscle weakness and elevated serum creatine kinase
concentration.
Pulmonary ﬁbrosis (PF) was deﬁned as bibasilar interstitial
ﬁbrosis on chest high resolution computed tomography
(HRCT). Pulmonary ﬁbrosis was graded by radiologist
according to the extent of involvement, grade l: basal and sub-
pleural, grade 2: basal and mid-zonal, grade 3: extensive ﬁbro-
sis ± bronchiectasis. In addition, pulmonary function tests,
including vital capacity of lungs (VC%) and forced expiratory
volume in the ﬁrst, second FEV1, FEV1/FVC (FEV1%)were
also evaluated to examine the severity of PF. Restrictive lung
disease was diagnosed if FVC, percent of predicted value
was <80% with FEV1/FVC actual value in the normal range
(more than 80%).
Restrictive lung disease was classiﬁed into mild, moderate
and severe according to the FVC percent of predicted value
as follows: mild restriction if FVC was 79–70%, moderate
restriction 69–50%, and severe restriction if FVC was less than
50%. Obstructive pattern was diagnosed if FEV1/FVC actual
value <80% [23].
Demographic and clinical characteristics of SSc patients are
shown in (Table 1).
3.2. ELISA for sFKN
Human sFKN levels were measured in serum samples by
ELISA according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA), using 96 well polystyrene
plates coated overnight at 25 C with 2 mg/ml of puriﬁed
goat antihuman FKN IgG. Brieﬂy, after being washed,plates were blocked for 1 h at 20 C with phosphate buffered
saline containing 1% bovine serum albumin and 5% su-
crose. Recombinant human FKN and serum samples were
added in triplicate, and the plates were incubated for 2 h
at 20 C. After further washing, plates were incubated with
biotinylated goat antihuman FKN Ab (250 ng/ml) for 2 h
at 20 C and then with streptavidin-peroxidase for 1 h at
20 C. Samples were developed with 0.1 ml/well of tetra-
methylbenzidine substrate diluted in citrate–phosphate buf-
fer. Reactions were stopped by adding 1 M H2SO4 and
absorbance was read at 450 nm.
3.3. Flow cytometric analysis
Fractalkine receptor CX3CR1 expression was studied on T-
lymphocyte subpopulations of whole blood samples. The
Tow-color analysis was performed with a combination of
FITC conjugated anti-CX3CR1 (Medical and Biological Lab-
oratories Corp, UK) and phycoerythrin conjugated anti-CD4
(Coulter Corp, Miami, FL), anti-CD8 (Coulter Corp), anti-
CD14 (Coulter Corp), or anti-CD16 monoclonal Abs (Coulter
Corp). The blood samples were stained at 4 C with a predeter-
mined optimal concentration of the test monoclonal Ab for
20 min, as previously described [18]. Blood erythrocytes were
lysed after staining with the Coulter whole blood immunolyse
kit as detailed by the manufacturer (Coulter Corp). Cells were
washed and analyzed with an FACS Caliber ﬂow cytometer
(BD PharMingen, San Diego, CA). Positive and negative pop-
ulations of cells were determined with unreactive isotype
matched monoclonal Abs (Coulter Corp) as controls for back-
ground staining.
Statistics. Data were analyzed using SPSS version 11.5
Descriptive statistics were done by number and percent as well
as mean and SD. Unpaired Student’s t-test was used for com-
parison of frequencies, and Spearman’s rank correlation coef-
ﬁcient was used to examine the relationship between two
continuous variables. Values of P< 0.05 were considered
signiﬁcant.4. Results
4.1. Serum sFKN levels in SSc patients and healthy controls
As shown in Table 2 and Fig. 1 SSc patients have signiﬁcant
elevation of sFKN levels than healthy controls (468 ± 160
vs 87 ± 20 pg/ml, P< 0.01).
4.2. Expression of CX3CR1 on PBMCs in SSc patients and
healthy controls
As shown in Table 2 and Fig. 2, the raised levels of
CX3CL1 in SSc patients were accompanied by an increase
in its receptor CX3CR1 on PBMCs. Regarding T cell sub-
types CD4
+ T cells, CD8
+ T cells and CD14
+ T cells, there
were signiﬁcant differences between SSc patients and healthy
controls (5.8 ± 1.1, 6.9 ± 2.1 and 8.2 ± 3.3 vs 2.1 ± 0.7,
2.6 ± 1.5 and 3.2 ± 1.9, P< 0.05), respectively. But there
was no signiﬁcant difference regarding CD16
+ T cells be-
tween SSc patients and healthy controls (14.6 ± 5.6 vs
10.1 ± 5.6 P> 0.05).
Table 1 Demographic and clinical characteristics of SSc
patients.
Patient characteristics
(n= 18)
Values
Continuous variables
(mean + SD)
Age 37.3 + 4.2
Disease duration (years) 7.8 + 5.4
Modiﬁed Rodnan skin
score
26.7 + 2.3
Categorical variables
[n(%)]
Pitting scars or skin
ulcers
13(72%)
Contracture of
phalanges
16(89%)
Diﬀuse pigmentation 11(61%)
Raynaud’s phenomenon 18(100%)
Pulmonary ﬁbrosis on
(HRCT)
11(61%)
FVC <80% 11(61%)
Arthritis 7(37%)
Dysphagia 18(100%)
Heart (pericarditis,
arrythmia)
4(22%)
Anticentromere
antibody
5(28%)
Anti-topoisomerase1
antibody
16(89%)
CRP 9(50%)
FVC: forced vital capacity of lungs.
CRP: C reactive protein.
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Figure 2 Expression of CX3 CR1 in SSc patients and controls.
Table 3 Clinical and laboratory data in SSc patients having
raised or normal sFKN levels.
Raised sFKN
(n= 10)
Normal
sFKN (n= 8)
Continuous
Variables
(mean ± SD)
Age 35.12 ± 11.90 40.57 ± 11.17
Disease
duration (years)
8.40 ± 7.09 7.40 ± 6.12
Rodnan skin
score
35.9 ± 10.99* 21.1 ± 7.19
Categorical
variables [n(%)]
Pitting scars or
skin ulcers
7(70%)* 5(36%)
Contracture of
phalanges
9(90%) 7(88%)
Diﬀuse
pigmentation
6(60%) 5(63%)
Raynaud’s
phenomenon
10(100%) 8(100%)
Pulmonary
ﬁbrosis on
(HRCT)
9(90%)* 2(25%)
FVC <80% 9(90%)* 2(25%)
Arthritis 4(40%) 3(38%)
Dysphagia 10(100%) 8(100%)
Anticentromere
antibody
3(30%) 2(25%)
Anti-
topoisomerase
antibody
7(70%)* 3(38%)
CRP 7(70%)* 2(25%)
* P< 0.05 vs SSc patients with normal sFKN levels.
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Figure 1 Serum levels of sFKN among SSc patients and
controls. Also among patients with PF(+) and patients without
PF().
Table 2 Serum sFKN (CX3CL1) and expression of its
receptor (CX3CR1) in SSc patients and controls.
sFKN (pg/ml) Patients (n= 18) Controls (n= 15) P<0.05
468 ± 160 87 ± 20
CX3CR1 expression
CD4 5.8 ± 1.1 2.1 ± 0.7 <0.05
CD8 6.9 ± 2.1 2.6 ± 1.5 <0.05
CD14 8.2 ± 3.3 3.2 ± 1.9 <0.05
CD16 14.6 ± 5.6 10.1 ± 5.6 >0.05
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Raised serum sFKN levels were seen in 10/18 (56%) of all pa-
tients, out of them 90% had pulmonary ﬁbrosis with a signif-
icant difference between them and control group, P< 0.05
(Table 3). SSc patients with PF had sFKN levels three times
Table 4 Correlations between serum sFKN and studied
variables in SSc patients.
Variables r P
Age 0.210 >0.05
Disease duration 0.123 >0.05
FVC% 0.916 <0.05
Pulmonary ﬁbrosis 0.762 <0.05
Rodnan skin score 0.661 <0.05
Pitting scars or skin ulcers 0.452 <0.05
Anti-topoisomerase antibody 0.792 <0.05
CRP 0.541 <0.05
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298 ± 125 pg/ml, P< 0.05), respectively (Fig. 1). SSc patients
with raised sFKN levels more frequently had high mRSS, pit-
ting scars, skin ulcers, decreased FVC%, anti-topoisomerase1
antibody and CRP than those with normal sFKN levels
P< 0.05 (Table 3).
4.4. Correlation between CX3CL1 levels and studied variables in
SSc
Serum sFKN levels correlated inversely with FVC% in SSc pa-
tient (r= 0.916, P< 0.05), but there was a signiﬁcant posi-
tive correlation between sFKN and pulmonary ﬁbrosis
(r= 0.762, P< 0.05), modiﬁed Rodnan skin score
(r= 0.661, P< 0.05), pitting scars or skin ulcers (r= 0.452,
P< 0.05) anti-topoisomerase 1antibody (r= 0.792,
P< 0.05) and CRP (r= 0.541, P< 0.05) (Table 4).
Thus, sFKN levels not only correlated with the extent of
skin sclerosis but also with the severity of PF in SSc patients.5. Discussion
The etiology of SSc is subject to ongoing research, as the pre-
cise events that underlie the development of this disease remain
unclear. The pathogenesis is known to involve endothelium,
epithelium, ﬁbroblasts, innate and adaptive immune systems
and their component immunological mediators. Endothelial
cell dysfunction may be the initiating factor, but the precise
triggering event(s) remain elusive. Vasculopathy shows similar-
ities in different organs (e.g. pulmonary hypertension, renal
disease and digital tip ulcer).Serum sFKN is a potent mediator
of vasculopathy, and hence represents a highly relevant target
for intervention of vascular features in SSc [24].
In the present study we show that SSc patients are charac-
terized by markedly increased serum levels of CX3CL1,
accompanied by the enhanced expression of its corresponding
receptor, CX3CR1 on peripheral blood mononuclear cell
(PBMC) than in healthy controls (P< 0.005, Table 2). These
ﬁndings suggest that enhanced sFKN–CX3CR1 interaction
contributes to the disease process. These results are in accor-
dance with [15,11,18] who concluded that raised sFKN pro-
motes CX3CR1 cell inﬁltration into the affected tissue
leading to tissue inﬂammation, because sFKN enhances the
chemotactic activity of cells expressing CX3CR1.
Previously, increased CX3CL1 expression has been found
in various autoimmune and vasculitic disorders such as SLEand rheumatoid arthritis, potentially contributing to neuropsy-
chiatric manifestations and synovitis, respectively 12. Studies
in animal model have shown that CX3CL1, inhibition may de-
lay the initiation and progression of lupus nephritis [25].
In this study CX3CL1 and its receptor CX3CR1 were signif-
icantly increased in patients with PF than in patients without
PF as evidenced by HRCT (P< 0.05, Fig. 1), pulmonary
ﬁbrosis (PF) was signiﬁcantly detected in patients with raised
sFKN than in patients with normal sFKN (P< 0.05). Fur-
thermore, serum sFKN was negatively correlated with
FVC% of lungs (Table 4).
Consistent with our result was the study of Hasegawa et al;
[18] which revealed that serum sFKN levels were signiﬁcantly
associated with the involvement and severity of pulmonary
ﬁbrosis by recruiting CX3CR1 + cells to the affected lung.
Serum sFKN interacts with its unique receptor, CXCR1, to
effect ﬁrm adhesion of monocytes/macrophages, natural killer
(NK) cells, and a subpopulation of T cells (CD8+ T cells,
CD4+ T cells) [26].
FKN exhibits efﬁcient chemotactic activity for monocytes/
macrophages, NK cells, and T cells expressing CX3CR1
[26,27]. Accumulating evidence suggests that sFKN–CX3CR1
interaction might contribute to the development of vascular in-
jury and inﬂammatory diseases, by recruiting activated leuco-
cytes [15,28].
Therefore, sFKN may have an important role in the induc-
tion and/or development of PF in SSc patients by recruiting
CX3 CR1 to the affected lungs [18]. The elevated sFKN levels
(in microscopic polyangitis patients and in all systemic vascu-
litis patients) correlated positively with vasculitis disease activ-
ity (Birmingham vasculitis activity score), C-reactive protein
levels, and erythrocyte sedimentation rate (ESR) [5]. Our re-
sults go hand in hand with the previous study where we found
positive correlation between sFKN and CRP.
In the current study, serum sFKN levels were correlated
positively with modiﬁed Rodnan skin score (Table 4). More-
over, digital ischemia and skin ulcers were found more fre-
quently in patients with raised sFKN levels than in patients
with normal serum sFKN levels.
Histological analysis of the initial stage of SSc shows the
presence of perivascular inﬁltrates of mononuclear cells in
the dermis, which is associated with increased collagen synthe-
sis in the surrounding ﬁbroblasts [29]. Consequently, our study
showed that patients with SSc had increasing serum sFKN and
its receptor CX3CR1 levels. Collectively, these observations
suggest that augmented expression of sFKN abnormally re-
cruits monocytes into the skin of SSc patients, mediating the
initiation and propagation of skin sclerosis. Recently Kasama
et al. [5], reported that up regulated expression of CX3 CR1 on
endothelial cells and the accumulation of activated inﬂamma-
tory cells would likely represent pathophysiologic events lead-
ing to skin vasculitis.
Previous ﬁndings indicated that circulating soluble prote-
ases such as granzyme may be linked to the pathogenesis of
endothelial injury in SSc [30,31]. Recently, it has been demon-
strated that CX3CR1 expression deﬁnes mononuclear cells
possessing high levels of intracellular perforin and granzyme
[32].These previous ﬁndings suggest that sFKN regulates
recruitment of cytotoxic cells through inﬂamed endothelium.
Therefore, sFKN may have a critical role in cytotoxic cell med-
iated endothelium damage, which may result in a vascular
injury.
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the pathogenesis of SSc, including tissue inﬂammation and
vascular injury, and its measurement may be a useful serologic
marker for the diagnosis and follow up of pulmonary and skin
complications.
Recommendation: Enhanced CX3CL1–CX3CR1 interaction
may be an important biologic factor in promoting endothelial
injury in SSc. So, further studies will clarify if strategies to tar-
get CX3CL1–CX3CR1 interaction could provide a new thera-
peutic approach in SSc, potentially by blocking endothelial cell
injury, leucocyte inﬁltration, and vascular injury.
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